^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Published date:
07/13/2017
Excerpt:
Blitzima is indicated for the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.
Secondary therapy:
CHOP
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
TRUXIMA (rituximab-abbs) is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with: Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens.
Secondary therapy:
CHOP
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial

Excerpt:
...Patient has relapsed or refractory CD20-positive disease following previous first-line systemic chemotherapy....
Trial ID: